ENLIVEX THERAPEUTICS LTD (ENLV) Stock News

USA - NASDAQ:ENLV - IL0011319527 - Common Stock

1.05 USD

0 (0%)

Last: 10/31/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ENLV Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Enlivex Therapeutics Ltd

Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025

4 days ago - By: Enlivex Therapeutics Ltd

Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025

a month ago - By: ACCESS Newswire - Mentions: LTRN

Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

a month ago - By: Enlivex Therapeutics Ltd

D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program

a month ago - By: Enlivex Therapeutics Ltd

D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program

a month ago - By: ACCESS Newswire - Mentions: SXTP

Enlivex Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

2 months ago - By: Enlivex Therapeutics Ltd

Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results

2 months ago - By: Enlivex Therapeutics Ltd

Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

2 months ago - By: Benzinga - Mentions: TNXP SNGX USBC BNR ...

12 Health Care Stocks Moving In Monday's Intraday Session

2 months ago - By: Enlivex Therapeutics Ltd

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

2 months ago - By: Enlivex Therapeutics Ltd

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

3 months ago - By: Enlivex Therapeutics Ltd

Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar

3 months ago - By: Enlivex Therapeutics Ltd

Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar

3 months ago - By: Enlivex Therapeutics Ltd

Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

3 months ago - By: Enlivex Therapeutics Ltd

Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

5 months ago - By: ACCESS Newswire - Mentions: FMST

Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

5 months ago - By: Enlivex Therapeutics Ltd

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology

5 months ago - By: Enlivex Therapeutics Ltd

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology

5 months ago - By: Enlivex Therapeutics Ltd

Enlivex Selected to Present at Israeli BioMed 2025 Conference

6 months ago - By: Enlivex Therapeutics Ltd

Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress

6 months ago - By: Enlivex Therapeutics Ltd

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

6 months ago - By: Enlivex Therapeutics Ltd

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

7 months ago - By: Enlivex Therapeutics Ltd

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

8 months ago - By: Enlivex Therapeutics Ltd

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

8 months ago - By: Enlivex Therapeutics Ltd

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

8 months ago - By: Enlivex Therapeutics Ltd

Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis

8 months ago - By: Enlivex Therapeutics Ltd

Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis

8 months ago - By: Enlivex Therapeutics Ltd

Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis

8 months ago - By: Enlivex Therapeutics Ltd

Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis

9 months ago - By: Enlivex Therapeutics Ltd

Enlivex Issues Urgent Statement on Fraudulent News Dissemination

9 months ago - By: Enlivex Therapeutics Ltd

Enlivex Issues Urgent Statement on Fraudulent News Dissemination

9 months ago - By: ACCESS Newswire - Mentions: ASPI NVA BFRG GRRR

RedChip Announces Webinar to Teach Investors How to Use RedChat, a Revolutionary AI Chatbot for Small-Cap Stock Analysis

a year ago - By: Enlivex Therapeutics Ltd

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

a year ago - By: Enlivex Therapeutics Ltd

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

a year ago - By: Enlivex Therapeutics Ltd

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis